Inside Precision Medicine Marketplace Translational Research QIAseq solutions for SARS-CoV-2

QIAGEN
QIAseq solutions for SARS-CoV-2

For targeted whole genome library preparation of SARS-CoV-2, the virus that causes COVID-19 disease

The QIAseq SARS-CoV-2 Primer Panel is specially designed to advance research into SARS-CoV-2, which is the causative agent of COVID-19 disease. This kit, when paired with a QIAseq FX DNA Library UDI Kit, is a solution for enriching and sequencing the entire viral genome. SARS-CoV-2 is encoded by a positive-sense, single-stranded RNA molecule that can be mixed with host RNA during isolation from a sample. The kit includes reagents to reverse transcribe the RNA into cDNA and primers to specifically enrich for its genome. The panel consists of over 200 primer pairs, covering the full 29.9 kb viral genome.




QIAGEN

19300 Germantown Road
Germantown, MD 20874
800-426-8157
https://www.qiagen.com





Features & Specs

  • High-fidelity reagents for reverse transcription and enrichment of SARS-CoV-2 RNA
  • When paired with a QIAseq FX DNA Library Unique Dual Index (UDI) Kit, multiplex 384 samples in a single run
  • Fast 3–3.5 hour enrichment workflow with limited hands-on time
  • Rapid sequence analysis, variant calling and phylogenetic analyses available using pre-built pipelines, when paired with the QIAGEN CLC Genomics Workbench software

Features & Specs

  • High-fidelity reagents for reverse transcription and enrichment of SARS-CoV-2 RNA
  • When paired with a QIAseq FX DNA Library Unique Dual Index (UDI) Kit, multiplex 384 samples in a single run
  • Fast 3–3.5 hour enrichment workflow with limited hands-on time
  • Rapid sequence analysis, variant calling and phylogenetic analyses available using pre-built pipelines, when paired with the QIAGEN CLC Genomics Workbench software
Inside Precision Medicine